{
  "docId": "019de076-5473-7242-b1c4-ab6acd3f6564",
  "docSlug": "198a0f3704f292567efe1a435af44ee8",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 39 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 39,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 30,
  "notes": "The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo across efficacy, safety, and administration metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-5473-7242-b1c4-ab6acd3f6564/14",
  "deckHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564",
  "deckJsonHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564.json",
  "deckAnchorHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "list",
      "text": "Target for Accelerated Approval in Second-Line NSCLC: 35% ORR, 6 months DoR. Target for Standard Approval: 20% improvement of OS vs. SoC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9e22fc8-47b1-47a4-b5b4-6c40cd58e0ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.96,
        "x": 0.02,
        "y": 0.385
      },
      "kind": "table",
      "text": "Comparison table of Indication, Target Population, Treatment, Expected Efficacy, Safety Profile, Administration, and Trial of Reference for three treatment arms.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9204eba0-9a16-4426-bb53-2faad8f846fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "THIO-101 – TARGET PROFILE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8550e6ca-1ae4-41be-baa7-609574493927",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 11,
      "beatId": "3607f1e8-344f-4fa2-80d9-afc52f26d638",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document presents an overview of MAIA Biotechnology's clinical trials and traction.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}